文献速递血液透析通路

前臂与上臂动静脉内瘘的纵向结局比较

Longitudinal outcomes of forearm versus upper arm arteriovenous fistulas.
PubMed 文献 · J Vasc Surg · 2025-06-07

基于三项前瞻性研究的多中心队列(1516例,2014-2019年),比较前臂与上臂动静脉内瘘(AVF)的3年通畅率、使用成功率及通路相关手缺血(ARHI)干预。前臂AVF与上臂AVF长期通畅率和12个月使用率无显著差异,但前臂AVF的ARHI干预风险更低(HR 0.36)。低容量中心前臂AVF的初级辅助通畅率和次级通畅率丢失风险更高。

要点

  • 前臂与上臂AVF的3年一期、一期辅助及二期通畅率无显著差异。
  • 前臂AVF的ARHI干预风险显著低于上臂AVF(HR 0.36)。
  • 低容量中心(≤30例/年)前臂AVF通畅率丢失风险显著高于上臂AVF。

核心结论

  • 前臂AVF与上臂AVF长期通畅率和使用率相似,但前臂AVF的ARHI干预率更低。
  • 前臂AVF结局似乎与机构容量相关,低容量中心结果显著更差。

研究设计与样本

  • 多中心队列研究,汇总HFM、PATENCY-1和PATENCY-2三项前瞻性研究数据。
  • 纳入1516例上肢AVF患者(2014-2019年),前臂AVF 1059例,上臂AVF 457例。
  • 平均年龄56.2±13.4岁,女性占25.2%。
  • 随访3年,采用Cox回归和logistic回归比较结局。

主要发现

  • 3年总体一期通畅率26.2%(95%CI 23.6%-29.1%),前臂与上臂AVF无显著差异。
  • 3年总体一期辅助通畅率57.6%(95%CI 54.6%-60.9%),前臂与上臂AVF无显著差异。
  • 3年总体二期通畅率66.5%(95%CI 63.6%-69.5%),前臂与上臂AVF无显著差异。

临床怎么用

  • 前臂AVF可作为符合条件的终末期肾病患者初始永久性血管通路的选项,其长期通畅率和使用率与上臂AVF相似。
  • 前臂AVF与较低的ARHI干预风险相关。
  • 在低容量中心(≤30例/年)创建前臂AVF时,需注意其通畅率丢失风险较高。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: National guidelines recommend forearm arteriovenous fistulas (AVFs) over upper arm AVFs as the initial permanent vascular access for hemodialysis if consistent with the end-stage kidney disease (ESKD) Life-Plan, but comparative outcomes are underexplored. Our objective was to assess longitudinal outcomes of forearm vs upper arm AVFs in patients with advanced kidney disease. METHODS: Using multicenter data from three prospective studies (Hemodialysis Fistula Maturation [HFM] Study, PATENCY-1 [A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula (AVF) Creation in Patients With Chronic Kidney Disease], and PATENCY-2), we conducted a cohort study of 1516 patients who underwent upper extremity AVF creation (2014-2019). Demographic factors, comorbidities, procedural details, and 3 years of longitudinal follow-up were captured. Outcomes included primary, primary-assisted, and secondary patency at 3 years, successful AVF use, and access-related hand ischemia (ARHI) interventions. Forearm vs upper arm AVF outcomes were compared using Cox regression and logistic regression models. Subgroup analyses included outcomes stratified by site volume using model interaction terms. RESULTS: The study population included 1059 forearm AVFs and 457 upper arm AVFs; mean age was 56.2 ± 13.4 years and 25.2% were female. The overall primary, primary-assisted, and secondary patency rates at 3 years was 26.2% (95% confidence interval [CI], 23.6%-29.1%), 57.6% (95% CI, 54.6%-60.9%), and 66.5% (95% CI, 63.6%-69.5%), respectively, with no significant differences between forearm and upper arm AVFs. Successful AVF use at 12 months was also similar between forearm (66.1%) and upper arm AVFs (70.0%) (odds ratio, 1.02; 95% CI, 0.71-1.48; P = .91). Forearm AVFs had lower risk of ARHI interventions (hazard ratio [HR], 0.36; 95% CI, 0.18-0.71; P = .003) compared with upper arm AVFs. Subgroup analyses showed that compared with upper arm AVFs, patients who received forearm AVFs at low volume sites (≤30 access creations per year) were at greater risk for loss of primary-assisted (HR, 2.03; 95% CI, 1.21-3.41; P < .001) and secondary patency (HR, 2.53; 95% CI, 1.33-4.83; P < .001). Patients receiving forearm AVFs at low volume sites also had lower AVF use at 12 months (odds ratio, 0.52; 95% CI, 0.21-1.31; P value of interaction = .03). CONCLUSIONS: Although forearm AVFs demonstrate similar long-term patency and usability as upper arm AVFs, they are associated with lower rates of ARHI. However, outcomes for forearm AVFs seem to have associations with institutional volume-significantly poorer results are seen at low-volume centers. System-level efforts are needed to improve outcomes for forearm AVFs, which serve as a critical lifeline for end-stage kidney disease patients.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Manchella MK, Appah-Sampong A, Ruan M, et al. Longitudinal outcomes of forearm versus upper arm arteriovenous fistulas. J Vasc Surg. 2025. PMID: 40490163. doi:10.1016/j.jvs.2025.05.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。